Please assess the completion status of the following clinical trial:

Trial Title: S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Partial onset seizures, whether or not secondarily generalized;~* at least 1 partial seizure and no more than 14 partial seizures per month as measured by historic baseline;~* using 1, but no more than 2 concomitant marketed antiepileptic drugs (AEDs) at the time of study entry.~Exclusion Criteria:~* Presence of known pseudoseizures within the last year;~* presence or history of allergy to the components of Keppra (levetiracetam, lactose, cornstarch, and excipients) or other pyrrolidine derivatives;~* on felbamate with less than 18 months exposure;~* on vigabatrin, but visual field had not been assessed as per recommendation of the manufacturer, i.e., every 6 months;~* uncountable seizures (clusters) or history of convulsive status epilepticus within the last 5 years.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).